Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CriVac
- Development stage
- Preclinical
- Lead developer
- CRI-Vac
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
CriVac is a proprietary vaccine platform technology that utilizes the non-pathogenic, monoxenous protozoan *Crithidia fasciculata* as a vehicle for the expression and delivery of recombinant antigens. Developed by the German biotechnology company CRI-Vac GmbH, the platform leverages the eukaryotic nature of *C. fasciculata* to produce complex proteins with post-translational modifications, such as glycosylation, which are often missing in bacterial expression systems. The protozoan can be engineered to either display antigens on its surface or secrete them, and the entire organism or its components can be used to stimulate the host's immune system. CriVac is designed to induce robust Th1-biased cellular and humoral immune responses, making it a candidate for vaccines against intracellular pathogens like *Leishmania*, as well as for cancer immunotherapy and COVID-19. The platform aims to provide a scalable and cost-effective alternative to traditional eukaryotic cell culture systems.
- Brand names
- CriVac
- Other names
- CRI-Vac
Beyond the preview
Go deeper on CriVac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CriVac.